JUBLINGREA - Jubilant Ingrevia Limited Share Price

Jubilant Ingrevia's management provided a positive outlook during the Q4 FY '26 Earnings Conference Call, highlighting a robust performance with the highest quarterly revenue and EBITDA in the last 14 quarters. The company reported Q4 revenue of Rs.1,179 crore, up 12% year-on-year, driven by a 10% volume growth. EBITDA stood at Rs.172 crore, up 11% year-on-year, while PAT was Rs.86 crore, reflecting a 17% increase year-on-year.

Management indicated that for FY '27, the company expects growth primarily from Specialty Chemicals and Nutrition segments, alongside a recovery in acetyls. They are optimistic about sequential growth in revenue and EBITDA starting from Q1 FY '27. A significant highlight is the anticipated 20% year-on-year EBITDA growth for the full fiscal year, alongside the successful construction of the Gajraula MPP plant, which will bolster the CDMO growth roadmap.

The recent acquisition of Remidex Pharma is expected to enhance the Human Nutrition business by providing integrated solutions to customers, with strong demand for niacinamide driving growth in the nutrition and personal care markets. Furthermore, an improved net debt-to-EBITDA ratio of 0.99x reflects a healthier balance sheet with a net debt reduction of 11% over the year.

Key forward-looking points include:

1. Dividends: A final dividend of Rs.2.5 per share was proposed, taking the total FY '26 dividend to Rs.5 per share, indicating a total cash outflow of Rs.79.8 crore.
2. Volume Growth: Resilience in the demand for chemicals, particularly in pharmaceuticals and agrochemicals, with robust export visibility.
3. CDMO Business Growth: The company expects the CDMO segment to grow at rates of 30% to 40%, as they continue to secure contracts with notable customers.

Overall, management's commentary reflects confidence in sustained growth trajectory and strategic investments aimed at enhancing operational efficiencies and expanding their market presence.

Major Questions and Answers from the Earnings Transcript

Question 1: Siddharth Gadekar from Equirus asked about the spreads in the Chemical Intermediates business for Q1 and potential inventory losses. Deepak Jain: I believe the benefit from our raw material inventory will continue in Q1, despite current acetic acid price declines. We strategically purchased inventory during high price periods, allowing us to offset any potential negative impacts from falling prices, ideally nullifying inventory losses by Q2.

Question 2: Siddharth Gadekar asked about the revenue growth of the CDMO business for FY26. Deepak Jain: Our CDMO business grew at nearly 30%-40% yearly. While we don't disclose specific figures, all CDMO revenues are currently included in Specialty Chemicals. We anticipate further acceleration in FY27 due to significant contracts.

Question 3: Inquired about the impact of ongoing projects and expected closures in FY27. Deepak Jain: We've secured 8 new molecules recently, with several in late stages. Though ramp-up takes time, we expect meaningful additions to our portfolio, impacting our financial results positively in the quarters ahead.

Question 4: Siddharth Gadekar questioned the benefits of the Remidex acquisition for Human Nutrition. Deepak Jain: Acquiring Remidex enables us to integrate further into Human Nutrition, allowing for product premixes and specialized offerings. We aim to leverage our existing customer relationships to rapidly scale this sector.

Question 5: Abhijit Akella asked about guiding sequential growth in EBITDA for FY27. Deepak Jain: We anticipate at least 20% annual growth in EBITDA for the full year. However, providing exact quarterly guidance remains challenging due to variability in contracts and timing.

Question 6: Abhijit Akella inquired about the contribution from the $300 million CDMO contract in the upcoming year. Deepak Jain: The contract started in March, and we're currently shipping materials. Firm volume determinations will follow discussions with the customer, forming a critical part of our revenue growth this year.

Question 7: Harsh Shah asked how the company plans to achieve ambitious growth targets over the next four years. Deepak Jain: We aim for 20-25% annual EBITDA growth based on diverse strategies outlined at our Investor Day. Consistent pricing will support our growth in the aim of 3x revenue and 4x EBITDA by FY30.

Question 8: Discussion about CDMO contracts from agrochemical majors beyond existing contracts. Deepak Jain: We have two executed contracts, and there are 6-8 additional opportunities in various stages of discussions with major agrochemical companies. Our execution capabilities have impressed these clients.

Question 9: Archit Joshi asked about recouping volumes with the innovator contract and overall growth drivers. Deepak Jain: We're maintaining a solid relationship with the innovator client. We expect them to support any volume shortfalls as per our agreement, ensuring we hit our bottom-line projections while focusing on growth through fine chemicals, CDMO, and nutrition.

Question 10: Nitesh Dhoot asked for updates on the smaller agri contract and growth potential. Deepak Jain: Conversations with the customer suggest a 4x to 5x scale-up potential from last year's execution, pending final volume confirmations amid market volatility.

Question 11: Nitesh Dhoot queried about the human-grade B3 plant's utilization and customer qualification. Deepak Jain: The PC-grade niacinamide is performing at 50% of estimated volumes, while the Niacin side is at 30-40% due to a later launch, gradually ramping up as projections stabilize.

These questions reflect key strategic areas for Jubilant Ingrevia, including growth prospects, challenges, and operational efficiencies.